The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.

MLA

Froud, Tatiana, et al. “The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy, and Metabolic Effects.” Transplantation, vol. 86, no. 1, July 2008, pp. 36–45. EBSCOhost, https://doi.org/10.1097/TP.0b013e31817c4ab3.

APA

Froud, T., Faradji, R. N., Pileggi, A., Messinger, S., Baidal, D. A., Ponte, G. M., Cure, P. E., Monroy, K., Mendez, A., Selvaggi, G., Ricordi, C., & Alejandro, R. (2008). The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation, 86(1), 36–45. https://doi.org/10.1097/TP.0b013e31817c4ab3

Chicago

Froud, Tatiana, Raquel N Faradji, Antonello Pileggi, Shari Messinger, David A Baidal, Gaston M Ponte, Pablo E Cure, et al. 2008. “The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy, and Metabolic Effects.” Transplantation 86 (1): 36–45. doi:10.1097/TP.0b013e31817c4ab3.